FIM+DASH: Food is Medicine Intervention to Promote Healthy Eating and Blood Pressure Control

Conditions

• Hypertension
• Hypertension (HTN)
• Obesity & Overweight

Eligibility Criteria

Sex

ALL

Age

N/A - N/A

Healthy Volunteers

Not accepted

Interventions

• FIM intervention arm — COMBINATION_PRODUCT
  For weeks 1-12: Culinary skill-building: 8 In-person and remote sessions will teach participants core techniques (knife skills, batch cooking, sodium-aware seasoning, whole-grain preparation, vegetable-forward entrées, low fat dairy use, lean-protein methods). DASH-friendly home food delivery. Participants will receive 12 weekly deliveries that provide items consistent with DASH (e.g., fruits/vegetables, low-fat dairy \[lactose-free available\], whole grains, lean proteins) dietary regimen. Participants will receive one-on-one support sessions with the interventionist to reinforce DASH adoption/adherence and HTN self-management tasks. For weeks 13-24, self-monitoring of BP and weight twice monthly continues via the text platform.
• FIM Usual Care Arm — COMBINATION_PRODUCT
  FIM Usual care arm (control) receives usual clinical care during the 24-week period, with limited study contact outside scheduled data-collection visits; after completing all study visits, control participants receive the post-study materials

Study Details

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Key Dates

Start date

Mar 1, 2026

Status verified

Sep 2025

Primary completion

Mar 31, 2029

Completion

Jun 30, 2029

Study Design

Enrollment

150 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Arms

• Active Comparator: FIM Usual Care Arm
• Experimental: FIM Intervention Arm

Primary Outcome Measure

blood pressure [ Time Frame: From enrollment to the end of treatment at 12 weeks, then at 24 weeks (maintenance phase) ]

Locations (4)

Find similar trials in Chicago, IL

Related Studies

• A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
  PHASE3 · Enrolling By Invitation · United Therapeutics · Phoenix, Arizona
• Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
  Recruiting · Duke University · Phoenix, Arizona
• Community Intervention to Reduce CardiovascuLar Disease in Chicago
  Recruiting · Northwestern University · Chicago, Illinois
• Church-based Intervention to Improve Blood Pressure in African Americans
  Recruiting · Rush University Medical Center · Chicago, Illinois